Edgewise Therapeutics, Inc. EWTX Business Segments — Depreciation Nonproduction

Similar metrics at other companies

POWISingle Reportable — Depreciation

$6.38M-11.9%

BOOTSingle Reportable — Depreciation

$20.1M+23.3%

MMSISingle Reportable — Cost Depreciation Amortization And Depletion

$50.06M+23.5%

PAYOSingle Reportable — D&A

$18.92M+31.5%

SRRKSingle Reportable — D&A

$335K-14.8%

FOURReportable Segment — Depreciation, Depletion and Amortization, Nonproduction

$94M+67.9%

Questions, answered.

What is Edgewise Therapeutics, Inc.'s business segments — depreciation nonproduction?

Edgewise Therapeutics, Inc. (EWTX) reported business segments — depreciation nonproduction of $537K in Q1 2026.

How has Edgewise Therapeutics, Inc.'s business segments — depreciation nonproduction changed year-over-year?

Edgewise Therapeutics, Inc.'s business segments — depreciation nonproduction increased by 4.5% year-over-year, from $514K to $537K.

What is the long-term trend for Edgewise Therapeutics, Inc.'s business segments — depreciation nonproduction?

Over 2 years (2023 to 2025), Edgewise Therapeutics, Inc.'s business segments — depreciation nonproduction has grown at a 15.9% compound annual growth rate (CAGR), from $1.55M to $2.09M.

What does business segments — depreciation nonproduction mean?

Represents the systematic allocation of the cost of tangible assets not directly involved in production, such as office equipment or laboratory furniture. This metric reflects the consumption of fixed assets over their useful lives in a non-manufacturing context. It is a standard measure of the capital intensity of the company's administrative and research infrastructure.